Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)

✍ Scribed by O’Brien, Mary E.R.; Gaafar, Rabab M.; Popat, Sanjay; Grossi, Francesco; Price, Allan; Talbot, Denis C.; Cufer, Tanja; Ottensmeier, Christian; Danson, Sarah; Pallis, Athanasios; Hasan, Baktiar; Van Meerbeeck, Jan P.; Baas, Paul

• Book ID: 121343618
• Publisher: Elsevier Science
• Year: 2013
• Tongue: English
• Weight: 444 KB
• Volume: 49
• Category: Article
• ISSN: 0959-8049
• DOI: 10.1016/j.ejca.2013.05.008